Potassium Citrate Supplementation Decreases the Biochemical Markers of Bone Loss in a Group of Osteopenic Women: The Results of a Randomized, Double-Blind, Placebo-Controlled Pilot Study.

ABSTRACT: The relationship involving acid-base imbalance, mineral metabolism and bone health status has previously been reported but the efficacy of the alkalizing supplementation in targeting acid overload and preventing bone loss has not yet been fully elucidated. In this randomized, double-blind, placebo-controlled study, the hypothesis that potassium citrate (K citrate) modifies bone turnover in women with postmenopausal osteopenia was tested. Three hundred and ten women were screened; 40 women met the inclusion criteria and were randomly assigned to the treatment or the placebo group. They were treated with K citrate (30 mEq day^-1) or a placebo in addition to calcium carbonate (500 mg day^-1) and vitamin D (400 IU day^-1). At baseline and time points of 3 and 6 mo

SUBMITTER: Granchi D 

PROVIDER: S-EPMC6164684 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature